ESR1 and breast cancer: Indeed, in ERα+ breast cancer cells, high level of E2-induced NGB takes part in the ERα-dependent pathways committed to the anti-apoptotic response against oxidative stress [7] and paclitaxel, a chemotherapeutic agent [9]; moreover, NGB participates in the E2-induced anti-oxidant effects through the NRF-2 pathway [10].